| ||
| Company news Indianapolis Business Journal Roche Diagnostics will develop a tool to use alongside the Tarceva therapy for lung cancer patients, a drug made by Roche's pharmaceutical business. ... See all stories on this topic » | ||
| 9 Toys to Avoid This Holiday Season CBS MoneyWatch.com (blog) California, the International Agency for Research for Cancer and the European Union classify this chemical as a potential carcinogen, and in long-term ... See all stories on this topic » | ||
| Immunomedics Announces Outcome of 2010 Annual Meeting of Stockholders MarketWatch (press release) The second study, funded by the National Cancer Institute, evaluates the combination of veltuzumab and yttrium-90 labeled epratuzumab in patients with ... See all stories on this topic » |
| ||
| Non Small Cell Lung Cancer - vrho.com Information about Vacation Rental Homes by Owner, Lung Cancer, Lung Cancer Information, Lung Cancer Symptoms, Lung Cancer Stages, Staging, Lung Cancer ... vrho.com/result.php?Keywords... | ||
| Taxotere® (docetaxel) Injection Concentrate: Dosing for Advanced ... TAXOTERE®, as a single agent, is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after ... www.taxotere.ch/oncology/dosage.../dosing_guide_lung.aspx | ||
| Image: Non Small Cell Lung Cancer (NSCLC) part of Diabetes drugs ... Non Small Cell Lung Cancer (NSCLC). Views: 0. « Prev Next ». [ Close Window ]. Image. Non Small Cell Lung Cancer (NSCLC). Loading slideshow. ... www.allvoices.com/.../67629784-non-small-cell-lung-cancer-... | ||
| Roche obtains license for EGFR lung cancer assays and will develop ... data confirm activity and clinical benefit in advanced non-small cell lung cancer For non-US media only Milan, Italy, Ingelheim, Germany - Monday 11 October ... www.sourcews.com/roche-obtains-license-egfr-lung-cancer |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment